Journal Publications

2017


Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) (ONLINE). J Clin Oncol JCO, 2017.


2016


- Jiang S, Chen B, Tu D. Inference on treatment-covariate interaction based on a nonparametric measure of treatment effects and censored survival data. Statist Med n/a, 2016.


- Luo X, Li M, Xu G, Tu D. Survival analysis following dynamic randomization.


2015


- EBCTCG. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level


Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabi A, Vallis KA, White


Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours - Perspectives from clinical trials and clinical practice. Eur J Can 50: 2303-8, 2014.


2013


2012


- Jiang S, Tu D. Inference on the probability as a measurement of treatment effect under a density ratio model and random censoring. Computational Statistics and Data Analysis 56: 1069-78, 2012.


• Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D,


- Meyer RM, Stanton HA, Parulekar WR, Saad F. Cooperative Group Cancer Clinical

- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrilis IL, Pritchard KL. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 128: 401-9, 2011.


• Sargent D, Shi Q, Yothers G, Van CE, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de GA. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C98903. Eur J Cancer 47: 990-6, 2011.


2010


- Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC Clinical Trials Group Working


- McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK,


- Zhu L, Tan X, Tu D. Testing the homogeneity of two survival functions against a mixture

2009


- Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal


Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to
determine progression-free and overall survival benchmarks for future phase II trials. J

  Seung SJ, Crott R, Uyl-de Groot CA. Cost-effectiveness of temozolomide for the

- Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J,
  Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Phase I and pharmacokinetic
  study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine
  kinases, in combination with carboplatin and paclitaxel in patients with advanced non-
  small cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J

  EA, Synold TW, Wainman N, Seymour L. A phase II study of ispinesib (SB-715992) in
  patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of

- Li X, Wu Y, Tu D. A Bartlett type correction for Wald test in Cox regression model.

- Liu S, Tu D. On the applications of Fisher's least significant difference (LSD) procedure
  in three-arm clinical trials with survival endpoints. Drug Information Journal 42: 81-91,
  2008.

  Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF,
  Robidoux A, Hoehn JL, Ingle JN, Geyer Jr CE, Costantino JP, Wolmark N. Benefit from
  exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-
  to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J

  Hantel A, Thomas J, Fuchs CS. Impact of body mass index and weight change after
  treatment on cancer recurrence and survival in patients with stage III colon cancer:

- Mitry E, Fields ALA, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D,
  O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E,
  Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative
  resection of metastases from colorectal cancer. A pooled analysis of two randomzied

- Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ,
  Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of
  life in older women with early-stage breast cancer treated with letrozole or placebo after

- NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive
  care improves survival in advanced non-small-cell lung cancer: A systematic review and
  meta-analysis of individual patient data from 16 randomized controlled trials. J Clin

- Oza AM, Eisenhauer EA, Elit L, Cutz J-C, Sakurada A, Tsao MS, Hoskins PJ, Biagi J,
  Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of
  erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 26:

- Parulekar WR, McKenzie M, Chi KN, Klotz L, Catton C, Brundage M, Ding K, Hiltz A,


**2007**


• Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D,
Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


recurring or refractory multiple myeloma (E1A95) a trial of the Eastern Cooperative Oncology Group. Cancer 106: 830-8, 2006.


Journal Publications
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom 70: 107-14, 2006.


2005


- Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, Lorimer I, Zhang T,


2004


• Eisenhauer E. Front-Line chemotherapy for ovarian cancer: which regimen and which


Fung KFM, Eisenhauer E, Elit L, Hirte H, Rosen B. Chemotherapy for recurrent epithelial


2001


2000

- Bramwell V, Andrusis I, Bell R, Eisenhauer E, Fornasier V, Kandel R, O'Sullivan B,


- Kirkbride P, Gelmon K, Eisenhauer E. Paclitaxel (Taxol) and concurrent radiotherapy in...

- Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Can 35: 1565-70, 1999.

1998

- Bramwell V, Blackstein M, Belanger K, Verma S, Beare S, Eisenhauer E. A phase II study of docetaxel in chemotherapy-naive patients with recurrent or metastatic adult soft


- Meta Analysis Group in Cancer. Efficacy of intravenous continuous infusion of


• Osoba D, Aaronson N, Zee B, teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research 6: 103-8, 1997.


1996


- Dent S, Eisenhauer E. Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-6, 1996.


- Shepherd FA, Latreille J, Crump M, Stewart D, Tomiak E, Eisenhauer E, Fisher B.


1995


1994


1992


1990


1989


1988


Johnston J, Eisenhauer E, Corbett WEN, Scott J, Zaentz S. The efficacy of


1987


1986


1985


1984


1980